ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NURO NeuroMetrix Inc

4.45
-0.02 (-0.45%)
Last Updated: 15:06:58
Delayed by 15 minutes
Share Name Share Symbol Market Type
NeuroMetrix Inc NASDAQ:NURO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -0.45% 4.45 4.40 4.45 4.45 4.3999 4.45 2,721 15:06:58

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

12/10/2022 8:47pm

GlobeNewswire Inc.


NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more NeuroMetrix Charts.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2022 to discuss its financial results as well as business developments affecting the Company.

For participants who wish to access the Earnings Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company’s website at www.NeuroMetrix.com. Following the conference call, a replay of the call will be available for one year on the Company's Investors section of the website.

About NeuroMetrix

NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through innovative medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® Fibromyalgia is a wearable neuromodulator that is the first and only FDA-authorized medical device to help reduce the symptoms of fibromyalgia. For more information, visit www.NeuroMetrix.com.

NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief Financial Officerneurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

1 Year NeuroMetrix Chart

1 Year NeuroMetrix Chart

1 Month NeuroMetrix Chart

1 Month NeuroMetrix Chart

Your Recent History

Delayed Upgrade Clock